Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen
- Development stage
- Approved
- Lead developer
- Merck
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen is a vaccine designed to prevent infections caused by Haemophilus influenzae type b (Hib), a bacterium responsible for severe diseases such as bacterial meningitis, pneumonia, sepsis, and epiglottitis in young children. The vaccine consists of the Hib capsular polysaccharide chemically linked (conjugated) to an outer membrane protein from Neisseria meningitidis. This conjugation enhances the immune response in infants and young children by promoting T-cell dependent immunity, leading to robust antibody production and long-term protection. The primary indication is prevention of invasive Hib disease in infants and young children; it may also be used in certain older children or adults with specific medical conditions[1][3][7].
- Brand names
- PedvaxhibVaxelisMenhibrix
- Other names
- Hib vaccineHaemophilus B conjugate vaccine
02
Targets
TLR2 (Toll-like Receptor 2)
Beyond the preview
Go deeper on haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen.